Organization
National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs
4 abstracts
Abstract
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.Org: Chongqing University Cancer Hospital, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy,
Abstract
First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University,
Abstract
Association of CAR-T cell secreting CD47 blocking protein with an enhanced antitumor activity in small cell lung cancer.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, West China Hospital, Chengdu, China,
Abstract
Clinical and molecular characteristics of multiple primaries identified by whole-exome sequencing-based genetic divergence in non-small-cell lung cancer.Org: Thoracic Oncology Ward, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,